Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Receivables - Net: 2023-2024

Historic Receivables - Net for Krystal Biotech (KRYS) over the last 2 years, with Dec 2024 value amounting to $104.7 million.

  • Krystal Biotech's Receivables - Net rose 33.23% to $129.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $129.6 million, marking a year-over-year increase of 33.23%. This contributed to the annual value of $104.7 million for FY2024, which is 149.16% up from last year.
  • According to the latest figures from FY2024, Krystal Biotech's Receivables - Net is $104.7 million, which was up 149.16% from $42.0 million recorded in FY2023.
  • Over the past 5 years, Krystal Biotech's Receivables - Net peaked at $104.7 million during FY2024, and registered a low of $42.0 million during FY2023.
  • In the last 2 years, Krystal Biotech's Receivables - Net had a median value of $73.4 million in 2023 and averaged $73.4 million.
  • Data for Krystal Biotech's Receivables - Net shows a peak YoY surged of 149.16% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Krystal Biotech's Receivables - Net stood at $42.0 million in 2023, then surged by 149.16% to $104.7 million in 2024.